MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer

MEASURE DESCRIPTION

Proportion of female breast cancer patients aged 18 to 70 with stage I (T1c) – III HER2 positive breast cancer receiving chemotherapy within 6 months of diagnosis and also receiving HER2-targeted therapy.

Relevance to Value Based Care

Clinical studies have shown that the administration of Trastuzumab or biosimilar significantly improves overall survival in patients with high-risk HER2 positive breast cancer.

 Numerator

Female breast cancer patients with AJCC stage I (T1c)– III, HER2 positive breast cancer.

 Denominator

Patients whose treatment course includes both chemotherapy within 6 months of diagnosis and HER2-targeted therapy. 

Exclusion/Exceptions

• Pregnancy

• Inbound after initiation of treatment

• Medical or patient reason for not administering HER2-targeted therapy

Scoring

Up to 10 points

 RESOURCES